According to Bespak, the company has joined the International Pharmaceutical Aerosol Consortium (IPAC), which is the parent organization of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Earlier this year, Bespak spun out of Recipharm, which joined IPAC-RS as a member in 2022.
Bespak will be represented on the IPAC board by Head of Strategic Marketing Louise Righton and by Business Development Director Simon Gardner. The company also announced that Director of Inhalation Sciences and Product Development Lei Mao was appointed Vice Chair of IPAC-RS as of July 2024, and Head of Drug Product Development Ross Errington has joined the IPAC-RS board.
The company emphasized its work with IPAC and IPAC-RS to advance the transition to LGWP propellants for MDIs. Bespak has previously announced the installation of LGWP-capable filling lines as well as partnerships related to LGWP transition services with H&T Presspart, Honeywell, and Oz-UK.
Bespak CEO Chris Hirst commented, “We are delighted to have the opportunity to collaborate with the inhalation community as IPAC and IPAC-RS members. It’s inspiring to us all to see the pharmaceutical industry at the forefront of the change to climate-friendly propellants. At Bespak, collaborating with our partners to bring greener, low GWP propellants to a product used by so many is something we are proud to be a part of. We are looking forward to working together with our industry peers in these two global consortiums to achieve a smooth transition that prioritizes the care of patients and respects our planet.”
Read the Bespak announcement.
